{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:37:15Z","timestamp":1792427835259,"version":"4.5.0"},"reference-count":27,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Voriconazole concentrations display a large variability, which cannot completely be explained by known factors. Inflammation may be a contributing factor, as inflammatory stimuli can change the activities and expression levels of cytochrome P450 isoenzymes. We explored the correlation between inflammation, reflected by C-reactive protein (CRP) concentrations, and voriconazole trough concentrations. A retrospective chart review of patients with at least one steady-state voriconazole trough concentration and a CRP concentration measured on the same day was performed. A total of 128 patients were included. A significantly (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.001) higher voriconazole trough concentration was observed in patients with severe inflammation (6.2 mg\/liter; interquartile range [IQR], 3.4 to 8.7 mg\/liter;\n                    <jats:italic>n<\/jats:italic>\n                    = 20) than in patients with moderate inflammation (3.4 mg\/liter; IQR, 1.6 to 5.4 mg\/liter;\n                    <jats:italic>n<\/jats:italic>\n                    = 60) and in patients with no to mild inflammation (1.6 mg\/liter; IQR, 0.8 to 3.0 mg\/liter;\n                    <jats:italic>n<\/jats:italic>\n                    = 48). The patients in all three groups received similar voriconazole doses based on mg\/kg body weight (\n                    <jats:italic>P<\/jats:italic>\n                    = 0.368). Linear regression analyses, both unadjusted and adjusted for covariates of gender, age, dose, route of administration, liver enzymes, and interacting coadministered medications, showed a significant association between voriconazole and CRP concentration (\n                    <jats:italic>P<\/jats:italic>\n                    &lt; 0.001). For every 1-mg\/liter increase in the CRP concentration, the voriconazole trough concentration increased by 0.015 mg\/liter (unadjusted 95% confidence interval [CI], 0.011 to 0.020 mg\/liter; adjusted 95% CI, 0.011 to 0.019 mg\/liter). Inflammation, reflected by the C-reactive protein concentration, is associated with voriconazole trough concentrations. Further research is necessary to assess if taking the inflammatory status of a patient into account is helpful in therapeutic drug monitoring of voriconazole to maintain concentrations in the therapeutic window, thereby possibly preventing suboptimal treatment or adverse events.\n                  <\/jats:p>","DOI":"10.1128\/aac.03820-14","type":"journal-article","created":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T04:27:40Z","timestamp":1410841660000},"page":"7098-7101","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":103,"title":["Inflammation Is Associated with Voriconazole Trough Concentrations"],"prefix":"10.1128","volume":"58","author":[{"given":"Marjolijn J. P.","family":"van Wanrooy","sequence":"first","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert F. R.","family":"Span","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Hematology, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G. G.","family":"Rodgers","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Critical Care, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin R.","family":"van den Heuvel","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Epidemiology, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald R. A.","family":"Uges","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjip S.","family":"van der Werf","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Departments of Internal Medicine and Pulmonary Diseases &amp; Tuberculosis, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos G. W.","family":"Kosterink","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands"},{"name":"University of Groningen, Department of Pharmacy, Division of Pharmacotherapy and Pharmaceutical Care, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Willem C.","family":"Alffenaar","sequence":"additional","affiliation":[{"name":"University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/525258"},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00626-12"},{"key":"e_1_3_1_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis599"},{"key":"e_1_3_1_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1570-1572.2006"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2009.02990.x"},{"key":"e_1_3_1_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/524669"},{"key":"e_1_3_1_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis437"},{"key":"e_1_3_1_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704828"},{"key":"e_1_3_1_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01316-08"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270008327537"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(03)80126-1"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/598327"},{"key":"e_1_3_1_14_2","doi-asserted-by":"publisher","DOI":"10.3109\/03602539709002246"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200645070-00002"},{"key":"e_1_3_1_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01992.x"},{"key":"e_1_3_1_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2003.01993.x"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2546-2553.2002"},{"key":"e_1_3_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2009.11.017"},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/21.1.114"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0736-4679(99)00135-3"},{"key":"e_1_3_1_22_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.107.015511"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.46.120604.141059"},{"key":"e_1_3_1_24_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389200043335559"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01221-08"},{"key":"e_1_3_1_26_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.6.731"},{"key":"e_1_3_1_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050615"},{"key":"e_1_3_1_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199902113400607"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03820-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.03820-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T17:43:33Z","timestamp":1645465413000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.03820-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1128\/AAC.03820-14"],"URL":"https:\/\/doi.org\/10.1128\/aac.03820-14","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"2014-07-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-09-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-11-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}